Back to results
US 2021/0277129 A1Published application
Antibodies and fusion proteins that bind to ccr8 and uses thereof
AssigneeGilead Sciences, Inc.
InventorsLara Lewis MCGRATH, Fabien DÉPIS, Changyun HU, Leonard G. PRESTA, Joshua Adam BUGGÉ
Life of this patent
Estimating the term…
Abstract
Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
Claims40
An isolated antibody that binds human CCR8, wherein the antibody comprises
- a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:
- 84 or 100, an HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 85, an HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 86, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 87, an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 88, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 89.
4 more elements
(canceled)
(canceled)
27-50. (canceled)
52-69. (canceled)
71-77. (canceled)
An isolated antibody that binds human CCR8, wherein:
- i) the antibody comprises a HCDR3 comprising SEQ ID NO:
- 86 or a variant of SEQ ID NO:
- 86 comprising 1, 2, or 3 mutations, and wherein the antibody binds to human CCR8 and possesses ADCC activity;
- or
- ii) the antibody comprises a HCDR3 that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
- 86, and wherein the antibody binds to human CCR8 and possesses ADCC activity.
3 more elements
79-115. (canceled)
117-161. (canceled)
Dependencies are inferred from the claim text.